Cited by 1,059Lung Cancer Treatments and MutationsHER2/EGFR in Cancer ResearchCancer Genomics and Diagnostics

The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.

Preexistence and Clonal Selection of MET Amplification in EGFR Mutant NSCLC

Open access

Turke, Alexa B., Zejnullahu, Kreshnik, Wu, Yi-Long, Song, Youngchul, Dias-Santagata, Dora, Lifshits, Eugene, Toschi, Luca, Rogers, Andrew, Mok, Tony, Sequist, Lecia, Lindeman, Neal I., Murphy, Carly, Akhavanfard, Sara, Yeap, Beow Y., Xiao, Yun, Capelletti, Marzia, Iafrate, A. John, Lee, Charles, Christensen, James G., Engelman, Jeffrey A., Jänne, Pasi A.·2010·Cancer Cell

DOI 10.1016/j.ccr.2009.11.022PMC PMC2980857

Open this paper in CoChat — free account Open PDF

Abstract

MET amplification activates ERBB3/PI3K/AKT signaling in EGFR mutant lung cancers and causes resistance to EGFR kinase inhibitors. We demonstrate that MET activation by its ligand, HGF, also induces drug resistance, but through GAB1 signaling. Using high-throughput FISH analyses in both cell lines and in patients with lung cancer, we identify subpopulations of cells with MET amplification prior to drug exposure. Surprisingly, HGF accelerates the development of MET amplification both in vitro and in vivo. EGFR kinase inhibitor resistance, due to either MET amplification or autocrine HGF production, was cured in vivo by combined EGFR and MET inhibition. These findings highlight the potential to prospectively identify treatment naive, patients with EGFR-mutant lung cancer who will benefit from initial combination therapy.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.ccr.2009.11.022

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261
Self-citation
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496
Self-citation
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors
Demetri, G. D., von Mehren, M., Blanke, C. D., Van den Abbeele, A. D., Eisenberg, B., Roberts, P. J., Heinrich, M. C., Tuveson, D. A., Singer, S., Janicek, M., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020461 · Cited by 4,389
EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044238 · Cited by 3,964
Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain
Pao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., & Varmus, H. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020073 · Cited by 3,527 · cited 2×
“Secondary mutations in EGFR itself, including the EGFR T790M ‘‘gatekeeper’’ mutation is observed in 50% of resistance cases, and amplification of the MET oncogene is observed in 20% of resistance cases (Balak et al., 2006; Bean et al., 2007; Engelman et al., 2007b; Kobayashi et al., 2005; Kosaka et al., 2006; Pao et a…”
Background
Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., & Sawyers, C. L. (2001) · Science · doi:10.1126/science.1062538 · Cited by 3,104
Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia Chromosome
Druker, B. J., Sawyers, C. L., Kantarjian, H., Resta, D. J., Reese, S. F., Ford, J. M., Capdeville, R., & Talpaz, M. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441402 · Cited by 2,713
Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer
Rosell, R., Moran, T., Queralt, C., Porta, R., Cardenal, F., Camps, C., Majem, M., Lopez-Vivanco, G., Isla, D., Provencio, M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904554 · Cited by 2,373
The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP
Yun, C.-H., Mengwasser, K. E., Toms, A. V., Woo, M. S., Greulich, H., Wong, K.-K., Meyerson, M., & Eck, M. J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709662105 · Cited by 2,118 · cited 2×
“To date, resistance mechanisms have predominately involved secondary genomic alterations in the target kinase that alter either the physical (such as steric hindrance) or biochemical (change in ATP affinity) properties of the receptor and result in drug resistance (Gorre et al., 2001; Shah et al., 2002; Yun et al., 20…”
Background
Detection of Mutations in EGFR in Circulating Lung-Cancer Cells
Maheswaran, S., Sequist, L. V., Nagrath, S., Ulkus, L., Brannigan, B., Collura, C. V., Inserra, E., Diederichs, S., Iafrate, A. J., Bell, D. W., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0800668 · Cited by 1,617
Self-citation

Show all 37 references

Sorted by citations

Items 701–800 of 1,000

Monitoring EGFR-lung cancer evolution: a possible beginning of a “methylation era” in TKI resistance prediction
Fabrizio, F. P., Sparaneo, A., & Muscarella, L. A. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1137384 · Cited by 14
PLEKHS1 drives PI3Ks and remodels pathway homeostasis in PTEN-null prostate
Chessa, T. A. M., Jung, P., Anwar, A., Suire, S., Anderson, K. E., Barneda, D., Kielkowska, A., Sadiq, B. A., Lai, I. W., Felisbino, S. L., et al. (2023) · Molecular Cell · doi:10.1016/j.molcel.2023.07.015 · Cited by 15
Real-World Data on Combined EGFR-TKI and Crizotinib Treatment for Acquired and De Novo MET Amplification in Patients with Metastatic EGFR-Mutated NSCLC
Urbanska, E. M., Grauslund, M., Koffeldt, P. R., Truelsen, S. L. B., Löfgren, J., Costa, J. C., Melchior, L. C., Sørensen, J. B., & Santoni‐Rugiu, E. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241713077 · Cited by 14
Acquired resistance to molecularly targeted therapies for cancer
Stubbs, N. M., Roady, T. J., Schwermann, M. P., Eteshola, E. O. U., MacDonald, W., Purcell, C., Ryspayeva, D., Verovkina, N., Tajiknia, V., Ghandali, M., et al. (2025) · Cancer Drug Resistance · doi:10.20517/cdr.2024.189 · Cited by 18
The effect of gefitinib in patients with postoperative recurrent non-small cell lung cancer harboring mutations of the epidermal growth factor receptor
Ko, R., Kenmotsu, H., Hisamatsu, Y., Akamatsu, H., Omori, S., Nakashima, K., Oyakawa, T., Wakuda, K., Shukuya, T., Ono, A., et al. (2014) · International Journal of Clinical Oncology · doi:10.1007/s10147-014-0761-8 · Cited by 14
Using Tandem Mass Spectrometry in Targeted Mode to Identify Activators of Class IA PI3K in Cancer
Yang, X., Turke, A. B., Qi, J., Song, Y., Rexer, B. N., Miller, T. W., Janne, P. A., Arteaga, C. L., Cantley, L. C., Engelman, J. A., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0445 · Cited by 14
Self-citation
Randomized phase 2 study of tivantinib plus erlotinib versus single-agent chemotherapy in previously treated KRAS mutant advanced non-small cell lung cancer
Gerber, D. E., Socinski, M. A., Neal, J. W., Wakelee, H. A., Shirai, K., Sequist, L. V. D., Rosovsky, R. P. G., Lilenbaum, R., Bastos, B. R., Huang, C. H., et al. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.01.010 · Cited by 14
Self-citation
Recent Advances in Curcumin Treated Non-Small Cell Lung Cancers: An Impetus of Pleiotropic Traits and Nanocarrier Aided Delivery
Malik, P., Hoidal, J. R., & Mukherjee, T. K. (2020) · Current Medicinal Chemistry · doi:10.2174/0929867327666200824110332 · Cited by 14
Cell Line Models for Acquired Resistance to First-Line Osimertinib in Lung Cancers—Applications and Limitations
Ohara, S., Suda, K., & Mitsudomi, T. (2021) · Cells · doi:10.3390/cells10020354 · Cited by 13
Phase 1 study of telisotuzumab vedotin in Japanese patients with advanced solid tumors
Fujiwara, Y., Kenmotsu, H., Yamamoto, N., Shimizu, T., Yonemori, K., Ocampo, C. J., Parikh, A., Okubo, S., Fukasawa, K., & Murakami, H. (2021) · Cancer Medicine · doi:10.1002/cam4.3815 · Cited by 14
MET Gene Dysregulation as a Promising Therapeutic Target in Lung Cancer—A Review
Terlecka, P., Krawczyk, P. A., Grenda, A., & Milanowski, J. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11121370 · Cited by 14
A novel lead compound CM-118
Meng, L., Shu, M., Chen, Y., Yang, D., He, Q., Zhao, H., Feng, Z., Liang, C., & Yu, K. (2014) · Cancer Biology & Therapy · doi:10.4161/cbt.28409 · Cited by 14
Clinical impact of high serum hepatocyte growth factor in advanced non-small cell lung cancer
Tsuji, T., Sakamori, Y., Ozasa, H., Yagi, Y., Ajimizu, H., Yasuda, Y., Funazo, T. Y., Nomizo, T., Yoshida, H., Nagai, H., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.17895 · Cited by 14
Tumor heterogeneity: does it matter?
Turnquist, C., Watson, R. A., Protheroe, A. S., Verrill, C. L., & Sivakumar, S. (2019) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2019.1667236 · Cited by 14
Pemetrexed/carboplatin plus gefitinib as a first-line treatment for EGFR-mutant advanced nonsmall cell lung cancer: a Bayesian network meta-analysis
Zhang, Z., Zeng, K., Zhao, S., Zhao, Y., Hou, X., Luo, F., Lu, F., Zhang, Y., Zhou, T., Ma, Y., et al. (2019) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835919891652 · Cited by 15
Cucurbitacin D Overcomes Gefitinib Resistance by Blocking EGF Binding to EGFR and Inducing Cell Death in NSCLCs
Hong, S. H., Ku, J. M., Lim, Y. S., Lee, S. Y., Kim, J. H., Cheon, C., & Ko, S. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00062 · Cited by 14
Clonal Neoantigen: Emerging “Mechanism-based” Biomarker of Immunotherapy Response
Nemunaitis, J. J., Stanbery, L., Willoughby, D., Bognar, E., Brun, S., Walter, A., Monk, B. J., Rocconi, R. P., Choucair, K., & Coleman, R. L. (2023) · Cancers · doi:10.3390/cancers15235616 · Cited by 14
The MET Oncogene: Thirty Years of Insights into Molecular Mechanisms Driving Malignancy
Crepaldi, T., Gallo, S., & Comoglio, P. M. (2024) · Pharmaceuticals · doi:10.3390/ph17040448 · Cited by 13
Potential Utility of a 4th-Generation EGFR-TKI and Exploration of Resistance Mechanisms—An In Vitro Study
Fukuda, S., Suda, K., Hamada, A., Oiki, H., Ohara, S., Ito, M., Soh, J., Mitsudomi, T., & Tsutani, Y. (2024) · Biomedicines · doi:10.3390/biomedicines12071412 · Cited by 14
New Targets in Non-Small Cell Lung Cancer
Gadgeel, S. M. (2013) · Current Oncology Reports · doi:10.1007/s11912-013-0326-4 · Cited by 13
Discovery of substituted 6-pheny-3H-pyridazin-3-one derivatives as novel c-Met kinase inhibitors
Kang, S.-T., Kim, E., Archary, R., Jung, H., Park, C. H., Yun, C., Hwang, J. Y., Choi, S. U., Chae, C. H., Lee, C. O., et al. (2014) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2014.08.067 · Cited by 13
Self-citation
Prognostic value of histogram analysis in advanced non-small cell lung cancer: a radiomic study
Virginia, B. M., Faivre, L., Rosellini, S., Ferrara, R., Facchinetti, F., Eva, H., Charles, F., Ammari, S., Michiels, S., Soria, J., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.22316 · Cited by 13
Multiplex Droplet Digital PCR Assay for Detection of MET and HER2 Genes Amplification in Non-Small Cell Lung Cancer
Oscorbin, I. P., Smertina, M. A., Pronyaeva, K. A., Voskoboev, M. E., Boyarskikh, U. A., Андреевич, К. А., Демидова, И. А., & Филипенко, М. Л. (2022) · Cancers · doi:10.3390/cancers14061458 · Cited by 13
EGFR and c-Met Inhibitors are Effective in Reducing Tumorigenicity in Cancer
Stone, A. (2014) · Journal of Carcinogenesis & Mutagenesis · doi:10.4172/2157-2518.1000173 · Cited by 12
miRNAs and resistance to EGFR—TKIs in EGFR-mutant non-small cell lung cancer: beyond ‘traditional mechanisms’ of resistance
Ricciuti, B. (2015) · ecancermedicalscience · doi:10.3332/ecancer.2015.569 · Cited by 13
Osimertinib Quantitative and Gene Variation Analyses in Cerebrospinal Fluid and Plasma of a Non-small Cell Lung Cancer Patient with Leptomeningeal Metastases
Song, Y., Liu, P., Huang, Y., Guan, Y., Han, X., & Shi, Y. (2018) · Current Cancer Drug Targets · doi:10.2174/1568009618666181017114111 · Cited by 13
Self-citation
Overcoming the Intrinsic Gefitinib-resistance via Downregulation of AXL in Non-small Cell Lung Cancer
Jeong, I., Song, J., Bae, S. Y., & Lee, S. K. (2019) · Journal of Cancer Prevention · doi:10.15430/jcp.2019.24.4.217 · Cited by 13
Dual inhibition of FOXM1 and its compensatory signaling pathway decreased the survival of ovarian cancer cells
Lee, D. W., Lee, W., Kwon, M., & Lee, H. N. (2020) · Oncology Reports · doi:10.3892/or.2020.7845 · Cited by 13
EGFR CA repeat polymorphism predict clinical outcome in EGFR mutation positive NSCLC patients treated with erlotinib
Winther‐Larsen, A., Nissen, P. H., Meldgaard, P., Weber, B., & Sørensen, B. S. (2014) · Lung Cancer · doi:10.1016/j.lungcan.2014.06.016 · Cited by 13
Discovery of substituted pyrazol-4-yl pyridazinone derivatives as novel c-Met kinase inhibitors
Kim, E. Y., Kang, S.-T., Jung, H., Park, C. H., Yun, C., Hwang, J. Y., Byun, B. J., Lee, C. O., Kim, H. R., Ha, J. D., et al. (2016) · Archives of Pharmacal Research · doi:10.1007/s12272-015-0703-7 · Cited by 13
Self-citation
Concurrent driver mutations/rearrangements in non-small-cell lung cancer
Tabchi, S., Kourié, H. R., & Klastersky, J. A. (2016) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000353 · Cited by 14
Spatial model predicts dispersal and cell turnover cause reduced intra-tumor heterogeneityPreprint
Waclaw, B., Bozic, I., Pittman, M. E., Hruban, R. H., Vogelstein, B., & Nowak, M. A. (2015) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/016824 · Cited by 13
Nanoenabled intracellular zinc bursting for efficacious reversal of gefitinib resistance in lung cancer
Li, J., Assaraf, Y. G., Zuo, W., Lin, Z., Leong, K. W., Zhao, Q., Zhu, L., & Kwok, H. F. (2024) · International Journal of Biological Sciences · doi:10.7150/ijbs.95929 · Cited by 12
Molecular Basis of Drug Resistance: Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors and Anaplastic Lymphoma Kinase Inhibitors
Yang, S. H. (2013) · Tuberculosis & respiratory diseases · doi:10.4046/trd.2013.75.5.188 · Cited by 11
Quantitative proteomics analysis identifies MUC1 as an effect sensor of EGFR inhibition
de Boer, H. R., Pool, M., Joosten, E., Everts, M., Samplonius, D. F., Helfrich, W., Groen, H. J. M., van Cooten, S., Fusetti, F., Fehrmann, R. S. N., et al. (2018) · Oncogene · doi:10.1038/s41388-018-0522-7 · Cited by 11
The secondary KIT mutation p.Ala510Val in a cutaneous mast cell tumour carrying the activating mutation p.Asn508Ile confers resistance to masitinib in dogs
Gentilini, F., Turba, M. E., Dally, C., Takanosu, M., Kurita, S., & Bonkobara, M. (2020) · BMC Veterinary Research · doi:10.1186/s12917-020-02284-9 · Cited by 12
Targeted Therapies with Chemoradiation in Esophageal Cancer: Development and Future Directions
Hong, T. S., Wo, J. Y.-L., & Kwak, E. L. (2012) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2012.09.004 · Cited by 12
Tailoring Tyrosine Kinase Inhibitors to Fit the Lung Cancer Genome
Looyenga, B. D., Cherni, I., MacKeigan, J. P., & Weiss, G. J. (2011) · Translational Oncology · doi:10.1593/tlo.10241 · Cited by 12
Hepatocyte growth factor reduces sensitivity to the epidermal growth factor receptor-tyrosine kinase inhibitor, gefitinib, in lung adenocarcinoma cells harboring wild-type EGFR
Yang, H., Wang, R., Peng, S., Chen, L., Li, Q., & Wang, W. (2016) · Oncotarget · doi:10.18632/oncotarget.7586 · Cited by 12
Molecular pathology in real time
Ryška, A. (2016) · Cancer and Metastasis Reviews · doi:10.1007/s10555-016-9607-3 · Cited by 12
Activity of Pan-Class I Isoform PI3K/mTOR Inhibitor PF-05212384 in Combination with Crizotinib in Ovarian Cancer Xenografts and PDX
Iezzi, A., Caiola, E., & Broggini, M. (2016) · Translational Oncology · doi:10.1016/j.tranon.2016.08.011 · Cited by 12
Unraveling Tumor Heterogeneity by Using DNA Barcoding Technologies to Develop Personalized Treatment Strategies in Advanced-Stage PDAC
Dujardin, P., Baginska, A. K., Urban, S., & Grüner, B. M. (2021) · Cancers · doi:10.3390/cancers13164187 · Cited by 12
Audit of Molecular Mechanisms of Primary and Secondary Resistance to Various Generations of Tyrosine Kinase Inhibitors in Known Epidermal Growth Factor Receptor-Mutant Non-small Cell Lung Cancer Patients in a Tertiary Centre
Suryavanshi, M., Jaipuria, J., Mattoo, S., Dhandha, S., & Khatri, M. (2022) · Clinical Oncology · doi:10.1016/j.clon.2022.06.003 · Cited by 13
Germline Met Mutations in Mice Reveal Mutation- and Background-Associated Differences in Tumor Profiles
Graveel, C. R., DeGroot, J. D., Sigler, R. E., & Woude, G. F. V. (2010) · PLoS ONE · doi:10.1371/journal.pone.0013586 · Cited by 12
Expressed Barcoding Enables High-Resolution Tracking of the Evolution of Drug Tolerance
Cotton, J. L., Estrada, J., Sagar, V., Chen, J. T., Piquet, M., Alford, J., Song, Y., Li, X., Riester, M., DiMare, M. T., et al. (2023) · Cancer Research · doi:10.1158/0008-5472.can-23-0144 · Cited by 12
Self-citation
Copy number gain of MET gene with low level in a metastatic lung adenocarcinoma patient represents response to salvage treatment with savolitinib and osimertinib: a case report
Wang, J., Dong, X., Liu, Y., Lin, K., & Chen, J. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1507677 · Cited by 11
Management of MET-Driven Resistance to Osimertinib in EGFR-Mutant Non-Small Cell Lung Cancer
Angelopoulos, P. A., Passaro, A., Attili, I., Aliaga, P. T., Corvaja, C., Spitaleri, G., Battaiotto, E., Signore, E. D., Curigliano, G., & de Marinis, F. (2025) · Genes · doi:10.3390/genes16070772 · Cited by 12
Current and future molecular profiling of cancer by next-generation sequencing: Table 1.
Shibata, T. (2015) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyv122 · Cited by 11
Mechanisms of resistance to reversible inhibitors of EGFR tyrosine kinase in non-small cell lung cancer
Krawczyk, P. A., Mlak, R., Powrózek, T., Nicoś, M., Kowalski, D. M., Wojas‐Krawczyk, K., & Milanowski, J. (2012) · Współczesna Onkologia · doi:10.5114/wo.2012.31768 · Cited by 10
MET inhibitors in advanced non-small-cell lung cancer: a meta-analysis and review
Kim, J. H., Kim, H. S., & Kim, B. J. (2017) · Oncotarget · doi:10.18632/oncotarget.20824 · Cited by 11
The hepatocyte growth factor/mesenchymal epithelial transition factor axis in high-risk pediatric solid tumors and the anti-tumor activity of targeted therapeutic agents
Grundy, M., & Narendran, A. (2022) · Frontiers in Pediatrics · doi:10.3389/fped.2022.910268 · Cited by 10
Targeting receptor tyrosine kinases in HER2-negative breast cancer
Anandappa, G., & Turner, N. C. (2013) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000021 · Cited by 11
Detection of MET and SOX2 amplification by quantitative real-time PCR in non-small cell lung carcinoma
Cai, Y., Zhang, H., Zhang, Z., Mu, J., & Li, Z. (2010) · Oncology Letters · doi:10.3892/ol.2010.229 · Cited by 11
Going beyond EGFR
Zimmermann, S., & Peters, S. (2012) · Annals of Oncology · doi:10.1093/annonc/mds319 · Cited by 11
An Overview, Current Challenges of Drug Resistance, and Targeting Metastasis Associated With Lung Cancer
Thakur, C. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-815720-6.00002-2 · Cited by 13
EGFR Gene Polymorphism Predicts Improved Outcome in Patients With EGFR Mutation-positive Non–small cell Lung Cancer Treated With Erlotinib
Winther‐Larsen, A., Ebert, E. B. F., Meldgaard, P., & Sørensen, B. S. (2019) · Clinical Lung Cancer · doi:10.1016/j.cllc.2019.02.011 · Cited by 11
Molecular Diagnostics in Non-Small Cell Lung Carcinoma
Sholl, L. M. (2020) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0039-3399564 · Cited by 11
Future perspectives from lung cancer pre-clinical models: new treatments are coming?
Bersani, F., Morena, D., Picca, F., Morotti, A., Tabbò, F., Bironzo, P., Righi, L., & Taulli, R. (2020) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-189 · Cited by 10
Parallel comparison and combining effect of radiomic and emerging genomic data for prognostic stratification of non‐small cell lung carcinoma patients
Kim, K. H., Kim, J., Park, H., Kim, H., Lee, S., Sohn, I., Lee, H. Y., & Park, W. (2020) · Thoracic Cancer · doi:10.1111/1759-7714.13568 · Cited by 11
Emerging immunological strategies: recent advances and future directions
Zhao, H., Luo, F., Xue, J., Li, S., & Xu, R. (2021) · Frontiers of Medicine · doi:10.1007/s11684-021-0886-x · Cited by 12
MET genetic lesions in non-small-cell lung cancer: pharmacological and clinical implications.
Zorzetto, M., Ferrari, S., Saracino, L., Inghilleri, S., & Stella, G. M. (2012) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2218-6751.2012.09.03 · Cited by 11
Mechanistic insights into acquired drug resistance in epidermal growth factor receptor mutation‐targeted lung cancer therapy
Ji, H. (2010) · Cancer Science · doi:10.1111/j.1349-7006.2010.01629.x · Cited by 11
MET Activation in Lung Cancer and Response to Targeted Therapies
Okun, S. A., Lu, D., Sew, K., Subramaniam, A., & Lockwood, W. W. (2025) · Cancers · doi:10.3390/cancers17020281 · Cited by 10
Multidrug Resistance: Are We Still Afraid of the Big Bad Wolf
Alhazza, A., Oyegbesan, A., Bousoik, E., & Aliabadi, H. M. (2025) · Pharmaceuticals · doi:10.3390/ph18060895 · Cited by 12
Clonal diversity shapes the tumour microenvironment leading to distinct immunotherapy responses in metastatic urothelial carcinoma
Kamatani, T., Umeda, K., Iwasawa, T., Miya, F., Matsumoto, K., Mikami, S., Hara, K., Shimoda, M., Suzuki, Y., Nishino, J., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-63309-1 · Cited by 10
Increased MET Gene Copy Number but Not mRNA Level Predicts Postoperative Recurrence in Patients with Non–Small Cell Lung Cancer
Kowalczuk, O., Kozłowski, M., Niklinska, W. E., Kiśluk, J., Niklińska, B., & Nikliński, J. (2014) · Translational Oncology · doi:10.1016/j.tranon.2014.08.002 · Cited by 10
Combined therapeutic potential of nuclear receptors with receptor tyrosine kinase inhibitors in lung cancer
Wairagu, P. M., Park, K. H., Kim, J., Choi, J.-W., Kim, H.-W., Yeh, B., Jung, S., Yong, S., & Jeong, Y. (2014) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2014.04.018 · Cited by 10
Amivantamab: TreatingEGFRExon 20–Mutant Cancers With Bispecific Antibody-Mediated Receptor Degradation
Köhler, J., & Janne, P. A. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.01494 · Cited by 11
Circulating Tumor DNA: Clinical Monitoring and Early Detection
Corcoran, R. B. (2018) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030518-055719 · Cited by 10
EGFR Mutant Lung Cancer
Gong, Y., & Pao, W. J. (2011) · Current topics in microbiology and immunology · doi:10.1007/82_2011_171 · Cited by 10
Updates on altered signaling pathways in tumor drug resistance
Li, X., Huang, X. Y., Chang, M., Lin, R., Zhang, J., & Lü, Y. (2024) · Visualized Cancer Medicine · doi:10.1051/vcm/2024007 · Cited by 9
The MET Oncogene: An Update on Targeting Strategies
Gallo, S., Folco, C. B., & Crepaldi, T. (2024) · Pharmaceuticals · doi:10.3390/ph17111473 · Cited by 9
Oncogenic MET as an Effective Therapeutic Target in Non–Small Cell Lung Cancer Resistant to EGFR Inhibitors: The Rise of the Phoenix
Trusolino, L. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-1181 · Cited by 9
Insight into the key features for ligand binding in Y1230 mutated c-Met kinase domain by molecular dynamics simulations
Yan, L., Zhang, L., Zhang, Y., Qiao, X., Pan, J., Liu, H., Lü, S., Xiang, B., Lu, T., & Yuan, H. (2017) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2017.1340852 · Cited by 9
Reversing MET‐Mediated Resistance in Oncogene‐Driven NSCLC by MET‐Activated Wnt Condensative Prodrug
Liu, N., Zheng, X., Yan, J., Jiang, A., Yao, Y., & He, W. (2024) · Advanced Science · doi:10.1002/advs.202400603 · Cited by 9
Molecular mechanisms contributing to resistance to tyrosine kinase-targeted therapy for non-small cell lung cancer.
Nurwidya, F., Murakami, A., Takahashi, F., & Takahashi, K. (2012) · Europe PMC (PubMed Central) · doi:10.3969/j.issn.2095-3941.2012.01.003 · Cited by 9
Molecular Therapeutic Advances in Personalized Therapy of Melanoma and Non-Small Cell Lung Cancer
Kelleher, F. C., Solomon, B., & McArthur, G. A. (2012) · Journal of Personalized Medicine · doi:10.3390/jpm2020035 · Cited by 9
Plasma dynamic monitoring of soluble c-Met level for EGFR-TKI treatment in advanced non-small cell lung cancer
Gao, H., Yang, J., Chen, Z., Zhang, X., Yan, H., Guo, W., Zhou, Q. H., Gou, L.-Y., Dong, Z., & Wu, Y.-L. L. C. (2016) · Oncotarget · doi:10.18632/oncotarget.9425 · Cited by 9
Self-citation
New systemic strategies for overcoming resistance to targeted therapies in non-small cell lung cancer
Genova, C., Rijavec, E., Biello, F., Rossi, G., Barletta, G., Bello, M. G. D., Vanni, I., Coco, S., Alama, A., & Grossi, F. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2016.1261109 · Cited by 9
Genetic evolution to tyrosine kinase inhibitory therapy in patients with EGFR-mutated non-small-cell lung cancer
Martínez‐Martí, A., Felip, E., Mancuso, F. M., Caratù, G., Matito, J., Nuciforo, P. G., Sansano, I., Mejia, N. M. D., Cedrés, S., Callejo, A., et al. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01558-9 · Cited by 10
Dynamics of preventive vs post-diagnostic cancer control using low-impact measures
Akhmetzhanov, A. R., & Hochberg, M. (2015) · eLife · doi:10.7554/elife.06266 · Cited by 9
Evolution of Relapse-Proficient Subclones Constrained by Collateral Sensitivity to Oncogene Overdose in Wnt-Driven Mammary Cancer
Keller, R. R., & Gunther, E. J. (2019) · Cell Reports · doi:10.1016/j.celrep.2018.12.096 · Cited by 9
[Research progress of the resistance mechanism of non-small cell lung cancer to EGFR-TKIs].
Liu, H., Wang, M., Hu, K., Xu, Y., Ma, M., Zhong, W., Zhao, J., Li, L., & Wang, H. (2013) · Europe PMC (PubMed Central) · doi:10.3779/j.issn.1009-3419.2013.10.07 · Cited by 9
Biophysical and structural characterization of the impacts of MET phosphorylation on tepotinib binding
Grädler, U., Schwarz, D. F., Wegener, A. A., Eichhorn, T., Bandeiras, T. M., Freitas, M. C., Lammens, A., Ganichkin, O. M., Augustin, M. A., Minguzzi, S., et al. (2023) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2023.105328 · Cited by 8
The molecular features of lung cancer stem cells in dedifferentiation process-driven epigenetic alterations
Masciale, V., Banchelli, F., Grisendi, G., Samarelli, A. V., Raineri, G., Rossi, T., Zanoni, M., Cortesi, M., Bandini, S., Ulivi, P., et al. (2024) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2024.107994 · Cited by 11
Schedule-dependent cytotoxic synergism of pemetrexed and erlotinib in BXPC-3 and PANC-1 human pancreatic cancer cells
Wang, L., Zhu, Z., ZHANG, W.-Y., & Zhang, W. (2011) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2011.293 · Cited by 8
RTK Inhibition: Looking for the Right Pathways Toward a Miracle
Xie, Q. R., Woude, G. F. V., & Berens, M. E. (2012) · Future Oncology · doi:10.2217/fon.12.130 · Cited by 8
Inhibition of Phospho-S6 Kinase, a Protein Involved in the Compensatory Adaptive Response, Increases the Efficacy of Paclitaxel in Reducing the Viability of Matrix-Attached Ovarian Cancer Cells
Choi, J. I., Park, S. H., Lee, H., Lee, D. W., & Lee, H. N. (2016) · PLoS ONE · doi:10.1371/journal.pone.0155052 · Cited by 8
Quantitative targeted proteomic analysis of potential markers of tyrosine kinase inhibitor (TKI) sensitivity in EGFR mutated lung adenocarcinoma
Awasthi, S., Maity, T. K., Oyler, B. L., Qi, Y. A., Zhang, X., Goodlett, D. R., & Guha, U. (2018) · Journal of Proteomics · doi:10.1016/j.jprot.2018.04.005 · Cited by 8
Single cell target gene mutation analysis by arc-edge-channel monolithic valve microfluidic cell isolation and locked nucleic acid-based PCR detection
Xu, T., Fu, H., Li, Y., Chen, X., Cheuk, W., Li, C., Zou, H., Yue, W., Au, S.-K. J., Wang, Y., et al. (2019) · Sensors and Actuators B Chemical · doi:10.1016/j.snb.2019.03.150 · Cited by 8
Dramatic Response to Lorlatinib in a Patient With CD74-ROS1-Positive Lung Adenocarcinoma With Acquired F2004V Mutation
Dimou, A., Ou, S. I., & Doebele, R. C. (2019) · JCO Precision Oncology · doi:10.1200/po.19.00013 · Cited by 8
Identification of a Three-Gene Signature Based on Epithelial-Mesenchymal Transition of Lung Adenocarcinoma Through Construction and Validation of a Risk-Prediction Model
Shi, J., Wang, Z., Guo, J., Chen, Y., Tong, C.-Y., Tong, J., Hu, W., Li, C., & Li, X. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.726834 · Cited by 8
Recent advances in lung cancer genomics: Application in targeted therapy
Pathak, N., Chitikela, S. D., & Malik, P. S. (2021) · Advances in genetics · doi:10.1016/bs.adgen.2021.08.004 · Cited by 9
Suppression of Chromosome Instability Limits Acquired Drug Resistance
Crowley, E. A., Hermance, N. M., Herlihy, C. P., & Manning, A. L. (2022) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-22-0263 · Cited by 8
Autocrine EGF and TGF ‐α promote primary and acquired resistance to ALK / c‐Met kinase inhibitors in non‐small‐cell lung cancer
Wang, Y., Zhang, Y., Chen, R., & Tian, X. (2022) · Pharmacology Research & Perspectives · doi:10.1002/prp2.1047 · Cited by 8
Single targeting of MET in EGFR-mutated and MET-amplified non-small cell lung cancer
Choi, Y., Kang, E. H., Kim, S., Park, S.-Y., Han, J., & Lee, Y. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02264-4 · Cited by 8
Prognostic implication of serum hepatocyte growth factor in stage II/III breast cancer patients who received neoadjuvant chemotherapy
Kim, H., Youk, J., Yang, Y., Kim, T., Min, A., Ham, H. S., Cho, S., Lee, K.-H., Keam, B., Han, S., et al. (2015) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-015-2072-5 · Cited by 8
Application of Single Cell Sequencing in Cancer
Yu, L., Zhao, H., Li, M., & Zhang, C. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-981-13-0502-3_11 · Cited by 8
Epidermal growth factor receptor T790M mutation: A major culprit in the progression of epidermal growth factor receptor-driven non-small cell lung cancer and the role of repeat biopsy
Aggarwal, S., Patil, S., & Rohtagi, N. (2017) · Indian Journal of Cancer · doi:10.4103/ijc.ijc_510_17 · Cited by 8
Les mutations des sites d’épissage de l’exon 14 de MET. Une nouvelle opportunité thérapeutique dans le cancer du poumon
Baldacci, S., Kherrouche, Z., Descarpentries, C., Wislez, M., Dansin, É., Furlan, A., Tulasne, D., & Cortot, A. B. (2018) · Revue des Maladies Respiratoires · doi:10.1016/j.rmr.2018.01.011 · Cited by 8

Authors: Turke, A. B., Zejnullahu, K., Wu, Y.-L., Song, Y., Dias-Santagata, D., Lifshits, E., Toschi, L., Rogers, A., Mok, T., Sequist, L., Lindeman, N. I., Murphy, C., Akhavanfard, S., Yeap, B. Y., Xiao, Y., Capelletti, M., Iafrate, A. J., Lee, C., Christensen, J. G., Engelman, J. A., & Jänne, P. A.
Affiliations: Harvard University (US)
Dana-Farber Cancer Institute (US)
Guangdong General Hospital (CN)
Massachusetts General Hospital (US)
Chinese University of Hong Kong (HK)
Brigham and Women's Hospital (US)
Pfizer (United States) (US)
Corresponding author: Engelman, Jeffrey A.
ORCID: Wu, Yi-Long
Song, Youngchul
Dias-Santagata, Dora
Toschi, Luca
Mok, Tony
Sequist, Lecia
Lindeman, Neal I.
Akhavanfard, Sara
Yeap, Beow Y.
Capelletti, Marzia
Iafrate, A. John
Lee, Charles
Christensen, James G.
Engelman, Jeffrey A.
Venue: Cancer Cell
Publisher: Elsevier BV
Published: 2010-01
Volume: 17
Issue: 1
Pages: 77-88
ISSN: 1535-6108 (ISSN-L)
DOI: 10.1016/j.ccr.2009.11.022
PMC: PMC2980857
OpenAlex: W1985264867
Cited by: 1,059
References: 37
Citations by year: 2026: 22 · 2025: 31 · 2024: 36 · 2023: 58 · 2022: 41 · 2021: 55 · 2020: 41 · 2019: 56 · 2018: 66 · 2017: 73 · 2016: 93 · 2015: 84 · 2014: 88 · 2013: 94 · 2012: 106
FWCI: 83.75
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/open-access/userlicense/1.0/ (vor, 1293 d)
Locations: Cancer Cell (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Funders: Guangdong Provincial Hospital of Traditional Chinese Medicine
University of Hong Kong
Chinese University of Hong Kong
National Institutes of Health
National Cancer Institute (P50CA127003, R01CA140594, R01CA114465, P50CA090578, R01CA135257, K08CA120060, R01CA137008)
Topics: Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
Keywords: MET amplification, EGFR mutation, non-small cell lung cancer, hepatocyte growth factor, clonal selection, combination therapy
MeSH terms: Animals, Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Gene Amplification, Humans, Lung Neoplasms, Mutation, Proto-Oncogene Proteins, Signal Transduction, Gene Expression, Polymerase Chain Reaction, Hepatocyte Growth Factor, In Situ Hybridization, Fluorescence, Receptors, Growth Factor, Drug Resistance, Neoplasm, Proto-Oncogene Proteins c-met, Xenograft Model Antitumor Assays, Cell Line, Tumor, Mice, Quinazolinones, ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Preexistence and Clonal Selection of MET Amplification in EGFR Mutant NSCLC

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks